Dr. Alter has been designated as a Distinguished NIH Investigator. Dr. Alter was co-discoverer of the Australia antigen that later proved to be a critical marker of the hepatitis B virus and was principal investigator in studies that identified non-A, non-B hepatitis and later showed its identity to HCV. His prospective studies traced the decline of post-transfusion hepatitis incidence from 30% in 1970 to near zero in 1997. Dr. Alter is recipient of the Clinical Lasker Award, the Canada Gairdner International Award, and has been elected to both the National Academy of Sciences and the National Academy of Medicine. In 2020 he was corecipient of the Nobel Prize in Physiology and Medicine and became the first NIH intramural clinical investigator to become a Nobel Laureate.
Dr. Harvey J. Alter receiving the Fray International Sustainability Award from Dr. Florian Kongoli at FLOGEN SIPS 2024
Dr. Florian Kongoli congratulating Dr. Harvey J. Alter during the FLOGEN SIPS 2024 award ceremony
Dr. Harvey J. Alter delivering an acceptance speech during the FLOGEN SIPS 2024 award ceremony
Prof. Harvey J. Alter winner of the Fray International Sustainability Award
Full video recording of the SIPS 2024 Summit Plenary Presentation of Dr. Harvey J. Alter 2019 Nobel Prize in Physiology or Medicine, and Distinguished NIH Investigator, USA, entitled: Hepatitis C the End of the Beginning and Possibly the Beginning of the End
Interview of Dr. Harvey J. Alter 2019 Nobel Prize in Physiology or Medicine, and Distinguished NIH Investigator, USA, given to Dr Florian Kongoli, FLOGEN Chairman